Niki Ntavari

Dr. Niki Ntavari

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Immunologic Research
Verified
Journal Article
Open access
PDF file
VSVasiliki Syrmou
Vasiliki Syrmou
CLChristos Liaskos
Christos Liaskos
NNNiki Ntavari
Niki Ntavari
KMKonstantinos Mitsimponas
Konstantinos Mitsimponas
TSTheodora Simopoulou
Theodora Simopoulou
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios
Several cases of vaccine-associated manifestations have been published including cases of inflammatory myositis. Herein, we comprehensively review the literature on the occasion of case of a woman with inflammatory myositis following COVID-19 vaccination. A 67-year-old woman presented with left arm edema, rash, and weakness after the 2nd dose of the BTN162b2 vaccine. Raised muscle enzymes and inflammatory markers with muscle edema on MRI and myositis findings on the electromyogram established the diagnosis. She was successfully treated with methylprednisolone pulses, intravenous immunoglobulin, methotrexate, and hydroxychloroquine. Cases of inflammatory myositis, dermatomyositis, or interstitial lung disease with myositis-specific autoantibodies or myositis-associated autoantibodies within 12 weeks from SARS-CoV-2 vaccination were included. Cases with malignancy, prior or subsequent COVID-19 infection, preexisting myositis/interstitial lung disease (ILD)/dermatomyositis (DM), or other connective tissue diseases were excluded. From our search, 49 cases were identified (mean age: 56.55 + 17.17 years), 59% were women, while 12 patients received the ChAdOx1 vaccine, 27 the BNT162b2, 8 the mRNA-1273, 1 the DB15806, and 1 the Ad26.COV2.S (overall, 70% received mRNA vaccines). Muscle involvement was the most common manifestation (79.5%), followed by skin involvement (53%) and ILD (34.6%), which were more common in the m-RNA vaccinees. Muscle biopsy, MRI findings, and autoantibody profile varied significantly, while successful immunosuppressive treatment was applied in most cases. Inflammatory myositis after COVID-19 vaccination has been well documented worldwide. Current evidence in support of a pathogenic link is challenging due to significant variation in clinical manifestations, radiological, histopathological, and immunological features.

25 November 2021 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
STSotirios G. Tsiogkas
Sotirios G. Tsiogkas
ΑMΑthanasios Mavropoulos
Αthanasios Mavropoulos
DSDimitrios N. Skyvalidas
Dimitrios N. Skyvalidas
EPEleni Patrikiou
Eleni Patrikiou
NNNiki Ntavari
Niki Ntavari
Bogdanos DimitriosBogdanos Dimitrios
Bogdanos Dimitrios

2 October 2023 in Medicina
Verified
Journal Article
Open access
PDF file
NNNiki Ntavari
Niki Ntavari
VSVasiliki Syrmou
Vasiliki Syrmou
KTKonstantinos Nikolaos Tourlakopoulos
Konstantinos Nikolaos Tourlakopoulos
Foteini MalliFoteini Malli
Foteini Malli
IGIrini Gerogianni
Irini Gerogianni
Ioannis PantazopoulosIoannis Pantazopoulos
Ioannis Pantazopoulos
Cutaneous tuberculosis (TB) is still a major public health problem worldwide. Tuberculosis verrucosa cutis (TBVC) is a cutaneous form of exogenous TB caused by exogenous reinfection in previously sensitized individuals. TBVC typically presents as a unifocal condition. Multifocal cutaneous lesions without any other tubercular foci are extremely rare in exogenous TB and few cases are reported in the literature. We describe the first case of multifocal TBVC in an 81-year-old Greek man. In total, 14 cases of multifocal TBVC have been reported in the literature (8 males and 6 females), with mean age 47.64 years (SD = 20.75) and mean time to diagnosis of 9.69 years (SD = 15.31). Most cases (11/12) responded rapidly to treatment, implying the accuracy of diagnosis, while no one was reported to be immunocompromised. Finally, in 10 cases (71.4%), history of skin microtrauma was reported (related either to daily life habits or to professional praxis), confirming it as the main risk factor. The tuberculin skin test was positive in 10 cases and tissue culture for mycobacteria was negative in all cases. TBVC can present with multiple lesions, even in countries where TB prevalence is not high, especially in patients with history of skin abrasions. Prompt specialist assessment can expedite the establishment of diagnosis.

11 January 2025 in Journal of Emergency Nursing
Verified
Journal Article
Closed access
NNNiki Ntavari
Niki Ntavari
GMGeorgios Mavrovounis
Georgios Mavrovounis
AGAgoritsa Gravani
Agoritsa Gravani
VSVasiliki Syrmou
Vasiliki Syrmou
ARAngeliki-Viktoria Roussaki
Angeliki-Viktoria Roussaki
Ioannis PantazopoulosIoannis Pantazopoulos
Ioannis Pantazopoulos

20 December 2024 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
EPEleni Patrikiou
Eleni Patrikiou
GEGeorge Efthymiou
George Efthymiou
CLChristos Liaskos
Christos Liaskos
NNNiki Ntavari
Niki Ntavari
TSThomas Scheper
Thomas Scheper
LSLazaros I. Sakkas
Lazaros I. Sakkas

18 May 2026 in Genes
Verified
Journal Article
Open access
PDF file
DTDimitra Eirini Triantafyllidi
Dimitra Eirini Triantafyllidi
VTVasiliki Tziouvara
Vasiliki Tziouvara
APAlexandros Pontikas
Alexandros Pontikas
AAAdam Akritidis
Adam Akritidis
CACharalabos Antonatos
Charalabos Antonatos
Yiannis VASILOPOULOSYiannis VASILOPOULOS
Yiannis VASILOPOULOS
Background/Objectives: We conducted the first pharmacogenetic investigation of atopic dermatitis in a cohort of 43 Greek patients, focusing on key variants within the IL6/JAK/STAT signaling axis, a pathway central to inflammation and therapeutic targeting. Methods: Patients receiving dupilumab, JAK inhibitors, or topical corticosteroids were prospectively evaluated, with treatment response assessed by changes in the Eczema Area and Severity Index over four months. Targeted genotyping of IL6R rs2228145 A>C, JAK1 rs2780815 T>G, and TRAF3 rs12147254 G>A were performed using PCR-RFLP. Results: Across the full cohort, no robust pharmacogenetic effects were detected, while baseline disease severity was the strongest predictor of absolute clinical improvement. However, stratified analyses revealed a significant association between the IL6R rs2228145 minor allele and reduced upadacitinib response (p-value = 0.026). Consistently, the same variant demonstrated a nominal association with reduced likelihood of achieving ≥75% improvement (p = 0.065). Conclusions: Although limited by sample size, these findings suggest potential treatment-specific pharmacogenetic effects within the IL6 pathway, supporting further investigation in larger cohorts to inform personalized therapeutic strategies in eczema.